EKF Diagnostics Reports 9.3% Growth in Adjusted EBITDA, Unveils Five-Year Strategic Plan

EKF Diagnostics' FY 2025 results show 9.3% adjusted EBITDA growth, thriving margins, strong cash flow & a clear five-year strategic blueprint. Analysis inside.

24 March 2026by Joshua Thompson6 min read66 views

This article covers information on EKF Diagnostics Holdings PLC.

LON:EKF

EKF Diagnostics FY 2025: margins up, cash flowing, strategy locked in

EKF Diagnostics has posted a tidy set of audited full-year results for 2025, showing the benefits of simplifying the portfolio and leaning into higher-margin lines. Revenue nudged up to £51.6m, but the real story is mix and margin: gross margin rose to 51% and adjusted EBITDA increased 9.3% to £12.4m. That improved profitability is being turned into cash, with £11.6m generated from operations and £5.0m returned via buy-backs.

Management has also set out a five-year strategic development plan focused on Point-of-Care (POC) Hematology leadership and scaling Life Sciences – with disciplined investment and a tighter commercial focus. Here’s what stands out and why it matters for investors.

Key numbers from EKF’s FY 2025 results

Metric	FY 2025	FY 2024	Comment
Revenue	£51.6m	£50.2m	+2.8%, driven by POC outside the US and β-HB in the US
Gross profit	£26.5m	£24.4m	2024 shown before exceptionals
Gross margin	51%	48%	Shift away from low-margin clinical chemistry
Adjusted EBITDA	£12.4m	£11.3m	+9.3%
Profit before tax	£7.1m	£6.3m	Up on stronger margins
Net cash from operations	£11.6m	£12.2m	Continues to be strong
Cash and cash equivalents	£15.8m	£14.3m	Includes £2.1m restricted in Russia
Share buy-backs	£5.0m	n/a	19,903,452 shares, 4.4% of issued at 31 Dec 2024
EPS (basic)	0.47p	1.38p	Tax charge drove lower bottom line
Effective tax rate	64%	Credit of 5%	Includes £1.3m German transfer pricing provision

Adjusted EBITDA is a measure of profit before interest, tax, depreciation and amortisation, adjusted for exceptional items and share-based payments – a common way to compare operating performance.

Point-of-Care Hematology and Diabetes: analyser seeding now, consumables later

POC revenue rose to £33.0m (2024: £31.4m), with improvements in both Hematology and Diabetes. The group placed over 16,000 POC analysers in 2025 and, crucially, over 16,000 Hematology analysers versus over 9,000 in 2024. That’s a big step-up in installed base.

Hematology revenue: £16.6m (2024: £15.8m)
Diabetes revenue: £12.1m (2024: £10.9m)
POC other: £4.3m (2024: £4.7m)

Why it matters: analysers are the razor, consumables are the blades. EKF sold almost 90 million individual test consumables in 2025. A much larger field of instruments should lift higher-margin consumables usage in the coming years. Capacity is being expanded too – a programme running through 2026-2027 aims to increase Hemo Control consumable production by 30%.

In the US, a dedicated sales team is targeting blood banks, plasma centres and WIC/Public Health channels – groundwork in 2025 that management expects to start paying off in 2026. Beyond the US, EKF is extending anaemia testing access in EMEA and LATAM, with new and extended contracts in Peru, Uganda and Kenya.

Share𝕏 in

Investing
Polar Capital Technology Trust Reports 102% NAV Growth in Stellar Fiscal Year
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Investing

Tagged

Last updated

5 July 2026

Star Rating

No ratings yet

Life Sciences: β-HB LiquiColor leads; CDMO ambitions building

Life Sciences revenue increased to £17.9m (2024: £16.7m), with β-HB sales up 10% to £13.8m, supported by white-label partners Thermo Fisher Scientific and Cardinal Healthcare. Fermentation (£2.6m) and Contract Manufacturing (£1.5m) were broadly flat, but EKF reports progress onboarding and developing clients.

Strategy-wise, the Life Sciences operation is being shaped into a Contract Development and Manufacturing Organisation (CDMO) aligned to Pharma, Biotech and Diagnostics. That shift, plus product updates to its class-leading β-HB LiquiColor reagent and a handheld multi-analyte POC testing programme, sets up potential product launches through 2027-2028.

Cash, buy-backs and balance sheet discipline

Operational cash generation remained robust at £11.6m, with year-end cash at £15.8m despite £5.0m of buy-backs and ongoing investment. The £3m HSBC revolving credit facility was cancelled and the £3.0m NASCIT facility (undrawn) is due to expire on 26 March 2026 and is not expected to renew. The company remains ungeared and focused on self-funded growth.

Dividends remain paused to prioritise investment and buy-backs. Management will consider resuming dividends when appropriate.

What dented EPS: a one-offish tax spike and tariff headwind

Despite stronger operating performance, reported EPS fell to 0.47p. The main driver was tax: a £4.6m income tax charge (64% effective rate) versus a credit in 2024, including £1.3m provided in Germany for transfer pricing and licence payments. The company expects the ongoing group tax rate to be lower than 2025, albeit higher than 2024 as past US tax advantages have been largely utilised.

Another watch item: from May 2025, higher US tariffs on goods imported from Germany reduced margins by £0.3m, with future tariff impacts uncertain due to contract pricing and policy variability.

Russia and geopolitical notes

EKF continues to supply essential medical products to its 60%-owned Russian subsidiary in line with sanctions guidance. Restricted cash in Russia increased to £2.1m (2024: £1.3m), and £0.5m of dividends were received in the year. Management flags ongoing uncertainty around access to cash and future distributions. The Middle East operations are currently unaffected by conflict, but the situation is being monitored closely.

Five-year strategic plan: what to watch next

Commercial focus – separate, strengthened sales and marketing teams for POC and Life Sciences already supporting β-HB growth.
Operational excellence – capacity expansion in Hematology consumables targeting +30% by 2027; some 2025 CapEx rolling into 2026.
Product development – β-HB reagent upgrades and handheld multi-analyte POC testing, with significant launches expected 2027-2028.
Hematology push – accelerated analyser placements globally to drive consumables; targeted US channels and expanded programmes in Africa, LATAM and APAC.

Specific numeric guidance for 2026 was not disclosed, but the company’s trajectory is “mapped to deliver further improvements in margin, revenue and EBITDA”.

Josh’s take: the bull and bear case, in plain English

Positives I like

Mix upgrade delivered: 51% gross margin and +9.3% adjusted EBITDA on modest revenue growth shows strategy is working.
Installed base flywheel: over 16,000 Hematology analysers placed should support higher recurring consumables revenue.
Cash generation and capital discipline: £11.6m generated from operations, £15.8m cash, £5.0m buy-backs, no bank debt.
β-HB momentum: 10% sales rise to £13.8m with blue-chip white-label partners provides credibility and runway.
Clear multi-year plan: capacity, product refresh and CDMO pivot give multiple shots on goal into 2027-2028.

Risks to keep on the radar

Tax volatility: 64% effective rate depressed EPS; management expects lower than 2025 going forward, but timing and magnitude are uncertain.
Tariffs: US tariffs on German-sourced POC goods clipped £0.3m from 2025 margins; future levels are unpredictable.
Russia exposure: £2.1m restricted cash and ongoing operational uncertainty could limit cash access.
Customer concentration: one customer represented 10.7% of revenue in 2025 – useful, but a concentration risk.
Execution risk: scaling capacity and delivering 2027-2028 product launches will need sustained investment and timelines can slip.

Where to learn more

Investor presentation: https://www.ekfdiagnostics.com/documents-reports.html
Investor Meet Company registration: https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor

Bottom line

EKF is doing the right things: simplify, focus, and scale what’s profitable. 2025 shows healthier margins, strong cash generation and tangible progress in Hematology placements and β-HB growth. The high tax charge and tariff noise cloud the statutory bottom line, but the operating trend is positive. If execution on capacity and product launches holds, the five-year plan gives credible scope for further margin and EBITDA improvement – with buy-backs adding support while valuation catches up with fundamentals.